| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5584037 | Seminars in Arthritis and Rheumatism | 2017 | 19 Pages |
Abstract
This study provided evidence that golimumab has high retention rate in real-life settings. SpA male patients with extra-articular manifestations, PsA patients on co-therapy with DMARDs, and RA patients attaining an early clinical response had the highest probability to continue golimumab over 2 years.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Florenzo MD, PhD, Leonardo MD, Maria Grazia MD, PhD, Romano MD, Angelo MD, Laura MD, Francesca MD, Antonio MD, Giorgio MD, Oriana MD, Fabio MD, PhD, Carmelo MD, Paola Chiara MD, Francesco Paolo MD, PhD, Maurizio MD, Giovanni MD,